NanoViricides' NV-387 Shows Promise in Reducing Metastatic Cancer Resurgence

NanoViricides reports that its broad-spectrum antiviral drug NV-387 could help reduce resurgence of metastatic cancer caused by viral infections. NV-387 has completed a Phase I clinical trial and is being advanced into Phase II clinical trials. Recent studies have linked viral infections to an increased risk of cancer resurgence, and NV-387 treatment could have a strong impact in treating cancer patients in remission who suffer from a viral infection.

NanoViricides, Inc. (NYSE American: NNVC) has reported significant progress in its efforts to combat viral-induced cancer resurgence. The company's broad-spectrum antiviral drug, NV-387, has successfully completed Phase I clinical trials and is now advancing into Phase II trials. This development comes on the heels of recent studies linking viral infections to an increased risk of cancer resurgence, particularly in patients in remission [1].

NV-387 is a unique antiviral drug that not only attacks the virus but also reduces inflammation, calming the human immune system. This dual action is crucial in preventing the awakening of "sleeping" cancer cells, which can be reactivated by viral infections. The drug has shown promise in reducing inflammation markers, particularly IL-6, which has been linked to an increased risk of cancer resurgence [1].

The company's President and Chairman, Anil R. Diwan, Ph.D., highlighted the potential impact of NV-387 on cancer patients in remission. "NV-387 treatment could have a strong impact in the treatment of cancer patients in remission who suffer from a viral infection that could lead to the cancer returning with metastasis to multiple sites in the body," he stated.

The need for NV-387 is underscored by the ongoing COVID-19 pandemic and the endemic nature of viruses like influenza and RSV, which continue to pose significant health risks. The drug has demonstrated exceptional efficacy in animal models against a range of lethal lung viral infections, including those caused by COVID-19, influenza, and RSV. In contrast, traditional antiviral drugs and vaccines often fail with new viral variants [2].

NanoViricides' platform technology, based on TheraCour's nanomedicine technology, is designed to address a wide range of viral diseases. The company's pipeline includes NV-387 for RSV, COVID-19, influenza, and other respiratory viral infections, as well as NV-HHV-1 for shingles. The company is also exploring the development of drugs against other viral diseases such as oral and genital herpes, HIV, and hepatitis C.

Despite the promising progress, the path to market for NV-387 remains uncertain. The drug development process is lengthy and requires substantial capital, and there is no guarantee that the drug will show sufficient effectiveness and safety for human clinical development. However, the potential impact of NV-387 on cancer patients in remission, coupled with the ongoing threat of viral infections, makes this a promising area of research.

References:
[1] https://news.cuanschutz.edu/cancer-center/covid-19-awaken-dormant-cancer-cells
[2] Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2025, August 18. https://covid.cdc.gov/covid-data-tracker